Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan R. Strosberg; Ghassan El-Haddad; Edward M. Wolin; Andrew Eugene Hendifar; James C. Yao; Beth Chasen; Erik Mittra; Pamela L. Kunz; Matthew H. Kulke; Heather A. Jacene; Dirk Jan Kwekkeboom; E.P. Krenning

doi:https://doi.org/10.1056/nejmoa1607427

doi.org/10.1056/nejmoa1607427

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan R. Strosberg

50

,

Ghassan El-Haddad

22

,

..., E.P. Krenning

22

Volume: 376, Issue: 2, Pages: 125 - 135

Published: Jan 12, 2017

Abstract

Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)–Dotatate in patients with advanced, progressive, somatostatin-receptor–positive midgut neuroendocrine...

Paper Fields

Paper Details

Title

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors

DOI

doi.org/10.1056/nejmoa1607427

Published Date

Jan 12, 2017

Volume

376

Issue

2

Pages

125 - 135

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors